Search

Your search keyword '"Kobayashi, Sayo"' showing total 4 results
Start Over Author "Kobayashi, Sayo" Topic hepatocellular carcinoma
4 results on '"Kobayashi, Sayo"'

1. Serum oxidative-anti-oxidative stress balance is dysregulated in patients with hepatitis C virus-related hepatocellular carcinoma

Author

Nishimura, Mamoru, Takaki, Akinobu, Tamaki, Naofumi, Maruyama, Takayuki, Onishi, Hideki, Kobayashi, Sayo, Nouso, Kazuhiro, Yasunaka, Tetsuya, Koike, Kazuko, Hagihara, Hiroaki, Kuwaki, Kenji, Nakamura, Shinichiro, Ikeda, Fusao, Iwasaki, Yoshiaki, Tomofuji, Takaaki, Morita, Manabu, and Yamamoto, Kazuhide

Subjects
congenital, hereditary, and neonatal diseases and abnormalities, anti-oxidant, virus diseases, chronic hepatitis C, oxidative stress, hepatocellular carcinoma, digestive system diseases
Abstract

Aim Oxidative stress is associated with progression of chronic liver disease (CLD). This association is best established in chronic hepatitis C. However, the anti-oxidative state is not well characterized. The objective of the present study was to investigate the balance of oxidative and anti-oxidative stress in CLD patients. Methods We recruited a study population of 208 patients, including healthy volunteers (HV; n = 15), patients with hepatitis B virus (HBV)-related CLD without or with hepatocellular carcinoma (HBV-non-HCC, n = 25, and HBV-HCC, n = 50, respectively), and patients with hepatitis C virus (HCV)-related CLD without or with HCC (HCV-non-HCC, n = 49, and HCV-HCC, n = 69, respectively). Serum levels of reactive oxygen metabolites (ROM) and anti-oxidative markers (OXY-adsorbent test; OXY) were determined, and the balance of these values was used as the oxidative index. Correlations among ROM, OXY, oxidative index and clinical characteristics were investigated. Results Patients with CLD exhibited elevated ROM and oxidative index compared to HV. Among patients with CLD, HCV positive status correlated with increased ROM. In CLD, HCV-HCC patients exhibited the highest ROM levels. Among HCV-related CLD patients, lower OXY correlated with HCC positive status, but was recovered by eradication of HCC. In HCV-HCC, lower OXY correlated with high PT-INR. Conclusion HCV positive CLD patients displayed higher oxidative stress and HCV-HCC patients displayed lower anti-oxidative state. Anti-oxidative state depression was associated with liver reservoir-related data in HCV-HCC and could be reversed with HCC eradication.

Published
2013

2. Clinical utility of serum fucosylated hemopexin in Japanese patients with hepatocellular carcinoma

Author

Kobayashi, Sayo, Nouso, Kazuhiro, Kinugasa, Hideaki, Takeuchi, Yasuto, Tomoda, Takeshi, Miyahara, Koji, Hagihara, Hiroaki, Kuwaki, Kenji, Onishi, Hideki, Nakamura, Shinichiro, Ikeda, Fusao, Miyake, Yasuhiro, Shiraha, Hidenori, Takaki, Akinobu, and Yamamoto, Kazuhide

Subjects
glycosylation, biomarker, hepatocellular carcinoma, fucosylated hemopexin, hypercarcinogenicity, digestive system diseases
Abstract

Aim: Hepatocellular carcinoma (HCC) is a common clinical problem all over the world. Fucosylated hemopexin (Fuc-Hpx) is a newly reported glycoprotein for the diagnosis of HCC, however, its clinical implications are unclear. The aim of this study was to elucidate the clinical utility of Fuc-Hpx in Japanese patients with HCC. Methods: The sera from 331 HCC patients, 45 with liver cirrhosis (LC), 85 with chronic hepatitis (CH) and 22 healthy people were examined for the expression of Fuc-Hpx; the level was compared with clinical parameters as well as hemopexin (Hpx) expression. The expressions of Fuc-Hpx in 12 HCC tissues and corresponding adjacent non-cancerous liver tissues were also examined. Results: No correlation was observed between Hpx and Fuc-Hpx level. The median Fuc-Hpx levels in healthy people and CH, LC and HCC patients were 3.8, 3.7, 6.1 and 7.6 AU/mL, respectively (CH vs LC, P = 0.002; CH vs HCC, P < 0.001; LC vs HCC, P = 0.02). Multivariate analysis revealed that low albumin, low prothrombin time and the presence of HCC were significantly correlated with high Fuc-Hpx (P = 0.013, =0.001 and

Published
2012

3. Evaluation of the effect of sorafenib using serum NX-des-γ-carboxyprothrombin in patients with hepatocellular carcinoma.

Author

Miyahara, Koji, Nouso, Kazuhiro, Morimoto, Yuki, Tomoda, Takeshi, Kobayashi, Sayo, Takeuchi, Yasuto, Hagihara, Hiroaki, Kuwaki, Kenji, Ohnishi, Hideki, Ikeda, Fusao, Miyake, Yasuhiro, Nakamura, Shinichiro, Shiraha, Hidenori, Takaki, Akinobu, and Yamamoto, Kazuhide

Subjects
LIVER cancer, BLOOD serum analysis, ANTINEOPLASTIC agents, CANCER invasiveness, HYPOXEMIA, VITAMIN K, BIOMARKERS
Abstract

Aim Des-γ-carboxyprothrombin ( DCP) is known to be increased by the use of sorafenib for the treatment of hepatocellular carcinoma ( HCC), despite its therapeutic efficacy. In addition to the tumor progression, hypoxia that impairs vitamin K uptake is known to induce DCP and this mechanism may explain DCP elevation by sorafenib. In this study, we tried to evaluate the effect of sorafenib treatment using a new marker, NX-DCP, which is specific to vitamin K absence. Methods Serum DCP and NX-DCP were measured in 50 consecutive HCC patients before and 1 week after starting sorafenib, and compared with the treatment effect using the modified Response Evaluation Criteria in Solid Tumors guidelines. Results DCP and NX-DCP increased 1.58- (median, range 0.21-28.7) and 1.20-fold (median, range 0.41-14.2) after the administration of sorafenib, respectively. The increases of both markers were less than twofold in approximately half of the patients (low-elevation group). However, 12 patients showed over twofold increase of both DCP and NX-DCP (double-elevation group), and eight patients showed over twofold increase of DCP alone ( DCP-elevation group). The disease control rate ( DCR) of the DCP-elevation group (12.5%) was significantly lower than those of the double-elevation group (75.0%, P = 0.020) and the low-elevation group (60.0%, P = 0.042). Progression-free survival ( PFS) was significantly shorter in the DCP-elevation group than in the double-elevation group ( P = 0.006) and the low-elevation group ( P = 0.001). Conclusion NX-DCP in combination with DCP could be a useful biomarker of sorafenib treatment for advanced HCC. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

4. Prognostic importance of fucosylated alpha-fetoprotein in hepatocellular carcinoma patients with low alpha-fetoprotein.

Author

Nouso, Kazuhiro, Kobayashi, Yoshiyuki, Nakamura, Shinichiro, Kobayashi, Sayo, Takayama, Hiroki, Toshimori, Junichi, Kuwaki, Kenji, Hagihara, Hiroaki, Onishi, Hideki, Miyake, Yasuhiro, Ikeda, Fusao, Shiraha, Hidenori, Takaki, Akinobu, Iwasaki, Yoshiaki, Kobashi, Haruhiko, and Yamamoto, Kazuhide

Subjects
ALPHA fetoproteins, LIVER cancer patients, ALANINE aminotransferase, TUMOR blood vessels, PORTAL vein
Abstract

Fucosylated alpha-fetoprotein (AFP-L3) is known to be a marker of poor prognosis in patients with hepatocellular carcinoma (HCC). However, it has been difficult to measure AFP-L3 under low AFP (≤ 20 ng/mL). The aim of this study was to elucidate the role of AFP-L3 in HCC patients with low AFP conditions. One hundred and ninety six consecutive newly developed HCC patients with low AFP (≤ 20 ng/mL) were examined for serum AFP-L3 expression by a newly-developed micro-total analysis system that could stably measure AFP-L3 in low AFP circumstances, and its clinical importance was analyzed. Positivity of AFP-L3 in HCC patients was 13.3% at a cut-off level of 10%. Five-year survivals of HCC patients with AFP-L3 (< 10%) and AFP-L3 (≥ 10%) were 69.4% and 41.1%, respectively ( P = 0.001). Among 18 clinical parameters, low alanine aminotransferase, large tumor size, presence of portal vein tumor thrombus, high AFP and high des-gamma carboxy prothrombin were observed in the high AFP-L3 (≥ 10%) group. Multivariate analysis revealed that high aspartate aminotransferase (AST) (risk ratio [RR] = 3.24, 95% confidence interval [CI] = 1.27-8.26), the presence of ascites (RR = 3.44, 95% CI = 1.22-9.34), multiple tumor number (RR = 3.06, 95% CI = 1.33-7.17), and high AFP-L3 (RR = 8.36, 95% CI = 2.79-25.5) were risk factors for survival. High AFP-L3 was also a risk factor for survival in HCC patients who received radiofrequency ablation ( P = 0.048). AFP-L3 is a strong prognostic factor for survival even in HCC patients with low AFP (≤ 20 ng/mL). [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results